Actin vs Eve
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
Eve
Best for **Women** seeking a women's-health-focused GLP-1 telehealth platform with dual access to either affordable compounded GLP-1 ($195/mo) OR brand-name FDA-approved Ozempic / Wegovy / Mounjaro ($1,399-$1,699/mo cash-pay), with LegitScript verification and a satisfaction guarantee. Strong fit for buyers who want a single platform supporting both ends of the compounded-vs-brand-name choice without switching providers.Starting at $195/mo
Side-by-Side Comparison
| Feature | Actin | Eve |
|---|---|---|
| Overall Score | 7.0/10 | 7.0/10 |
| Starting Price | ✓$133/mo | $195/mo |
| Editorial Rating | 3.5 ★ /5 | 3.5 ★ /5 |
| Features | 2 features | ✓11 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
Eve
Pros
- ✓**Women's-health-focused brand positioning** is genuinely differentiated — most DTC GLP-1 competitors default to gender-neutral or male framing; Eve fills a real market gap
- ✓**Dual modality access** (compounded + brand-name FDA-approved) — patients who prefer Wegovy/Ozempic/Mounjaro can access them on the same platform as compounded options; rare in the DTC directory (Brightmeds is the only other one)
- ✓LegitScript Certified with publicly verifiable ID (42862417) — strong trust signal beyond just the badge
- ✓Verbatim FDA compounded-medication disclaimer published — meets WLR transparency standard
- ✓Oral SUBLINGUAL semaglutide offered alongside injectable — auto-classifies into /best/oral-glp1-providers via description regex
- ✓'$0 unless approved' payment model reduces sign-up risk significantly
- ✓Satisfaction guarantee / money-back available
- ✓Free shipping above $50 threshold (most orders qualify)
Cons
- ✗Full states-served list NOT disclosed publicly — only implied via relocation-continuity framing
- ✗Specific 503A pharmacy partner NOT named
- ✗503A vs 503B compounding designation NOT specified
- ✗LegitScript ID published (42862417) but not embedded in text — only in the seal image
- ✗Named medical director / clinical leadership NOT disclosed
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed
- ✗Governing law / arbitration venue NOT publicly stated
- ✗Brand-name pricing ($1,399-$1,699/mo) is roughly retail cash-pay — does NOT appear to include savings card or insurance pathways; patients with insurance should price-compare elsewhere first
- ✗Subscription cancellation allowed but refund policy text not detailed publicly
Our Verdict
Both Actin and Eve score equally well overall — the right choice depends on your priorities. Choose Actin if you want affordable compounded semaglutide with B12 enhancement, or Eve if **Women** seeking a women's-health-focused GLP-1 telehealth platform with dual access to either affordable compounded GLP-1 ($195/mo) OR brand-name FDA-approved Ozempic / Wegovy / Mounjaro ($1,399-$1,699/mo cash-pay), with LegitScript verification and a satisfaction guarantee. Strong fit for buyers who want a single platform supporting both ends of the compounded-vs-brand-name choice without switching providers. matters most to you.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.